5-Fluorouracil, adriamycin, and BCNU (FAB) combination chemotherapy for advanced gastric cancer

Massimo Lopez, Carlo Federico Perno, Luigi Di Lauro, Paola Papaldo

Research output: Contribution to journalArticlepeer-review


Thirty-two evaluable patients with advanced measurable gastric adenocarcinoma were treated with a combination of 5-fluorouracil, adriamycin, and BCNU (FAB). Two complete and fourteen partial responses were observed, with an overall response rate of 50%. The median duration of response was 10 months, and the median survival of all 32 patients, 7 months. Responding patients had significantly better survival than the nonresponders (P60.001). Analysis of the results according to pretreatment performance status, resectability of the primary tumor, and histologic differentiation of the malignancy demonstrates that only the first influenced the therapeutic results. The FAB regimen was well tolerated, allowing administration of nearly the whole of the projected drug dosages during the course of the therapy in all but three patients. These results indicate that the FAB combination is an effective chemotherapeutic regimen in metastatic or locally advanced gastric carcinoma. Incorporation of this regimen into the design of combined-modality treatment would result in improved prognosis.

Original languageEnglish
Pages (from-to)194-197
Number of pages4
JournalCancer Chemotherapy and Pharmacology
Issue number3
Publication statusPublished - Apr 1984

ASJC Scopus subject areas

  • Pharmacology
  • Oncology
  • Cancer Research


Dive into the research topics of '5-Fluorouracil, adriamycin, and BCNU (FAB) combination chemotherapy for advanced gastric cancer'. Together they form a unique fingerprint.

Cite this